NIOSH EXPLORATORY/DEVELOPMENTAL GRANT PROGRAM (R21)
RELEASE DATE: December 4, 2003
PA NUMBER: PA-04-030
March 2, 2006 (NOT-OD-06-046) Effective with the June 1, 2006 submission date,
all R03, R21, R33 and R34 applications must be submitted through Grants.gov
using the electronic SF424 (R&R) application. Accordingly, this funding
opportunity expires on the date indicated below. A Replacement R21 (PAR-06-408)
funding opportunity announcement has been issued for the submission date of June 1, 2006
and submission dates thereafter.
EXPIRATION DATE for R21 Non-AIDS Applications: March 2, 2006
EXPIRATION DATE for R21 AIDS and AIDS-Related Applications: May 2, 2006
Department of Health and Human Services (DHHS)
PARTICIPATING ORGANIZATION:
Centers for Disease Control and Prevention (CDC)
(http://www.cdc.gov)
COMPONENT OF PARTICIPATING ORGANIZATION:
National Institute for Occupational Safety and Health (NIOSH)
(http://www.cdc.gov/niosh/homepage.html)
NOTE: THE POLICIES, GUIDELINES, TERMS, AND CONDITIONS STATED IN THIS
ANNOUNCEMENT MAY DIFFER FROM THOSE USED BY THE NIH.
CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER(S): CFDA 93.262
THIS PA CONTAINS THE FOLLOWING INFORMATION
o Purpose of the PA
o Research Objectives
o Mechanism of Support
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to send Inquiries
o Submitting an Application
o Peer Review Process
o Review Criteria
o Award Criteria
o Required Federal Citations
PURPOSE OF THIS PA
This PA supersedes all previous announcements of the NIOSH
Exploratory/Developmental Grants (R21) Program.
The NIOSH, CDC invite grant applications for research related to occupational
safety and health. NIOSH research programs support priority areas identified
in the National Occupational Research Agenda (NORA) as well as applications
aimed at reducing injury and illness in construction, transportation,
agriculture, mining, and health care, described in the RESEARCH OBJECTIVES
section which provides an example of NORA and other occupational safety and
health research program areas. Within CDC, the NIOSH is the lead Federal
Institute responsible for conducting research and making recommendations for
the prevention of work-related illnesses and injuries. Visit the NIOSH
homepage for a full description of occupational safety and health program
areas at http://www.cdc.gov/niosh/homepage.html.
The purpose of the NIOSH R21 is to encourage applications from institutions
that are interested in testing innovative or conceptually creative ideas that
are scientifically sound and may advance our understanding of safety and
occupational health. Another objective is to encourage necessary initial
development to provide a basis for important future research that can be used
in preventing occupational diseases and injuries. This purpose is shared by
other Centers of the Public Health Service (PHS) within the CDC.
RESEARCH OBJECTIVES
In today's society, Americans are working more hours than ever before. The
workplace environment profoundly affects health; simply by going to work each
day, we may face hazards that threaten our health and safety. Risking one's
life or health should never be considered merely part of the job. In 1970,
Congress passed the Occupational Safety and Health Act to ensure Americans the
right to "safe and healthful working conditions," yet workplace hazards
continue to inflict a tremendous toll in both human and economic costs.
Private industry employers reported 5.3 million work injuries in 2000 and
363,000 cases of occupational illness. An average of 16 American workers die
each day from injuries on the job (in 2000, there were 5915 fatal work
injuries). Moreover, even the most conservative estimates find that about 137
additional workers die each day from workplace diseases. Additionally, in
1999 occupational injuries and deaths cost $123 billion in wages and lost
productivity, administrative expenses, health care and other costs. This does
not include the cost of occupational disease. These occupational injuries and
diseases create needless human suffering, a tremendous burden upon health care
resources, and an enormous drain on U.S. productivity.
NIOSH is the lead Federal Institute responsible for conducting research and
making recommendations for the prevention of work related illnesses and
injuries. NIOSH=s mandate includes the support of research in numerous
occupational safety and health areas in addition to the topics identified in
the NORA, described below. Investigators are encouraged to discuss their
research topics with NIOSH program staff to determine the relevance to
occupational health and safety.
Because of the diverse nature of occupational safety and health issues, many
other research topics are supported by NIOSH in addition to the NORA topics.
Thus, NIOSH supports research in many other areas related to occupational
disease and injury including; violence, biomarkers, emergency response,
mining, bioterrorism, agricultural related illnesses and injuries, and other
occupational safety and health issues. Visit the NIOSH homepage for more
information on NIOSH=s research program areas at
http://www.cdc.gov/niosh/homepage.html.
In 1996, NIOSH and its partners in the public and private sectors developed
the NORA to provide a framework to guide occupational safety and health
research into the next decade. Approximately 500 organizations and
individuals outside NIOSH provided input into the development of NORA. The
agenda identifies 21 research priorities and reflects an attempt to consider
both current and emerging needs. The priority areas are not ranked; each is
considered to be of equal importance. The NORA priority research areas are
grouped into three categories: Disease and Injury, Work Environment and
Workforce, and Research Tools and Approaches.
NORA Priority Research Areas are:
Disease and Injury
1. Allergic and Irritant Dermatitis
2. Asthma and Chronic Obstructive Pulmonary Disease
3. Fertility and Pregnancy Abnormalities
4. Hearing Loss
5. Infectious Diseases
6. Low Back Disorders
7. Musculoskeletal Disorders of the Upper Extremities
8. Traumatic Injuries
Work Environment and Workforce
9. Emerging Technologies
10. Indoor Environment
11. Mixed Exposures
12. Organization of Work
13. Special Populations at Risk
Research Tools and Approaches
14. Cancer Research Methods
15. Control Technology and Personal Protective Equipment
16. Exposure Assessment Methods
17. Health Services Research
18. Intervention Effectiveness Research
19. Risk Assessment Methods
20. Social and Economic Consequences of Workplace Illness and Injury
21. Surveillance Research Methods
Potential applicants may obtain a copy of the publication "National
Occupational Research Agenda" (HHS, CDC, NIOSH Publication No.96-115) from the
NIOSH, telephone (800) 356-674 or on the internet at
http://www.cdc.gov/niosh/nora.html.
Applications responding to this announcement will be reviewed for their
responsiveness to program interests and their potential for developing
knowledge that can be used in preventing occupational diseases and injuries.
Applicants should provide a statement about which NIOSH research area is being
addressed and a rationale for how the proposal will contribute to the
specified priority area (this information should be placed in the "Background
and Significance" section of the "Research Plan" of the application).
Potential applicants with questions concerning the acceptability of their
proposed work are strongly encouraged to seek assistance from the NIOSH
program staff listed in this announcement under the section "Where to Send
Inquiries."
The R21 mechanism is intended to encourage new exploratory and developmental
research projects. For example, such projects could assess the feasibility of
a novel area of investigation or a new experimental system that has the
potential to enhance health-related research. Another example could include
the unique and innovative use of an existing methodology to explore a new
scientific area. These studies may involve considerable risk but may lead to a
breakthrough in a particular area, or to the development of novel techniques,
agents, methodologies, models or applications that could have major impact on
occupational safety and health research.
Translational research that is focused on bringing research results to the
workplace is a priority to NIOSH. Investigators are encouraged to conduct
projects in this emerging area.
Applications for R21 awards should describe projects distinct from those
supported through the traditional investigator initiated research project
grant (R01) mechanism. For example, long-term projects, or projects designed
to increase knowledge in a well-established area will not be considered for
R21 awards. Applications submitted under this mechanism should be exploratory
and novel. These studies should break new ground or extend previous
discoveries toward new directions or applications. Projects of limited cost
or scope that use widely accepted approaches and methods within well
established fields are better suited for the NIOSH R03 small grant mechanism.
Information on the R03 program can be in the National Institutes of Health
Guide.
MECHANISMS OF SUPPORT
This PA will use the NIOSH R21 Grant award mechanism. As an applicant, you
will be solely responsible for planning, directing, and executing the proposed
project. An individual may not receive more than one R21 award for this
announcement.
The applicant may request a project period of up to two years with a combined
budget for direct costs of up $275,000 for the two year period. Applications
exceeding $275,000 for the two year period will be considered unresponsive and
returned without further consideration. For example, the applicant may
request $100,000 direct costs in the first year and $175,000 direct costs in
the second year. The request should be tailored to the needs of the project.
Normally, no more than $200,000 may be requested in any single year.
This PA uses just-in-time concepts. It also uses the modular budgeting
format. (see http://grants.nih.gov/grants/funding/modular/modular.htm). All
applications submitted in response to this announcement must use the modular
budget format. This program does not require cost sharing as defined in the
current NIH Grants Policy Statement at
http://grants.nih.gov/grants/policy/nihgps_2001/part_i_1.htm.
Exploratory/developmental grant support is for new projects only; competing
continuation applications will not be accepted. Two revisions of a
previously reviewed exploratory/developmental grant application may be
submitted as defined in NIH Policy at
http://grants.nih.gov/grants/policy/amendedapps.htm.
Applications submitted in response to this program announcement follow the
standard receipt, review and award cycles, see
http://grants.nih.gov/grants/dates.htm for more information.
ELIGIBLE INSTITUTIONS
You may submit an application if your institution has any of the following
characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges, hospitals,
and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Domestic and foreign institutions/organizations
o Faith-based or community based organizations
o Indian Tribes, Tribal Government, College and/or Organizations.
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to develop
an application for support. Individuals from under-represented racial and
ethnic groups as well as individuals with disabilities are always encouraged
to apply for NIOSH/CDC programs.
SPECIAL REQUIREMENTS
Applicants are encouraged to use the NIOSH R21 to explore the feasibility of
an innovative research question or approach, which may not qualify through
existing research grant programs, or may not be competitive as a standard R01.
This award is not intended to supplement ongoing or other proposed research;
nor is it intended to be a mechanism for providing institutional support.
No minimum time commitment (percent effort) has been established for the R21
award, although the commitment should be appropriate to meet the goals of the
proposed investigation.
WHERE TO SEND INQUIRIES
We encourage your inquiries concerning this PA and welcome the opportunity to
answer questions from potential applicants. Inquiries may fall into two areas:
scientific/research and financial or grants management issues.
o Direct your questions about scientific/research issues to:
For exposure assessment method, control technology, emerging technology,
surveillance, and mixed exposure studies contact:
Susan B. Board, M.S.
Office of Extramural Programs
National Institute for Occupational Safety and Health
Centers for Disease Control and Prevention
1600 Clifton Road, N.E.
Executive Park Building 24, Room 1415, MS E-74
Atlanta, GA 30333
Telephone: (404) 498-2512
FAX: (404) 498-2517
Email: sboard@cdc.gov
For dermatitis, cancer research methods, fertility and pregnancy
abnormalities, hearing loss, health services research, infectious diseases,
indoor environment, organization of work, and special populations contact:
Adele Childress, Ph.D., M.S.P.H.
Office of Extramural Programs
National Institute for Occupational Safety and Health
Centers for Disease Control and Prevention
1600 Clifton Road, N.E.
Executive Park Building 24, Room 1429, MS E-74
Atlanta, GA 30333
Telephone: (404) 498-2509
FAX: (404) 498-2571
Email: achildress@cdc.gov
For asthma and COPD, social and economic consequences, intervention
effectiveness, musculoskeletal disorders, risk assessment methods, and
traumatic injuries and all other occupational safety and health issues
contact:
Michael J. Galvin, Jr., Ph.D.
Office of Extramural Programs
National Institute for Occupational Safety and Health
Centers for Disease Control and Prevention
1600 Clifton Road, N.E.
Executive Park Building 24, Room 1536, MS E-74
Atlanta, GA 30333
Telephone: (404) 498-2524
FAX: (404) 498-2571
Email: mgalvin@cdc.gov
Direct your questions about financial or grants management matters to:
Peter E. Grandillo Jr.
Acquisition & Assistance Field Branch
Centers for Disease Control & Prevention
626 Cochrans Mill Road
Pittsburgh, PA 15236-0070
Telephone: (412) 386-6834
Fax: (412) 386-6429
Email: PNG2@CDC.GOV
SUBMITTING AN APPLICATION
Applications must be prepared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). Applications must have a Dun and
Bradstreet (D&B) Data Universal Numbering System (DUNS) number as the
Universal Identifier when applying for Federal grants or cooperative
agreements. The DUNS number can be obtained by calling (866) 705-5711 or
through the web site at http://www.dunandbradstreet.com/. The DUNS number
should be entered on line 11 of the face page of the PHS 398 form. The PHS 398
is available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an
interactive format. For further assistance contact GrantsInfo, Telephone
(301) 710-0267, Email: GrantsInfo@nih.gov.
The title and number of this announcement must be typed on line 2 of the face
page of the application form and the YES box must be checked.
APPLICATION RECEIPT DATES: Applications submitted in response to this R21
program announcement will be accepted at the standard application deadlines,
which are available at http://grants1.nih.gov/grants/dates.htm. Application
deadlines are also indicated in the PHS 398 application kit.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of
the application, including the checklist, and five signed photocopies in one
package to:
Center for Scientific Review (CSR)
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
APPLICATION PROCESSING: Applications must be mailed on or before the receipt
dates described at
http://grants.nih.gov/grants/funding/submissionschedule.htm. The CSR will
not accept any application in response to this PA that is essentially the same
as one currently pending initial review unless the applicant withdraws the
pending application. The CSR will not accept any application that is
essentially the same as one already reviewed. This does not preclude the
submission of a substantial revision of an unfunded version of an application
already reviewed, but such application must include an Introduction addressing
the previous critique.
Although there is no immediate acknowledgement of the receipt of an
application, applicants are generally notified of the review and funding
assignment within 8 weeks.
PEER REVIEW PROCESS
Applications submitted for this PA will be assigned on the basis of
established PHS referral guidelines. An appropriate scientific review group
convened in accordance with the standard NIH peer review procedures
(http://www.csr.nih.gov/refrev.htm) will evaluate applications for scientific
and technical merit.
As part of the initial merit review, all applications will:
o Undergo a selection process in which only those applications deemed to have
the highest scientific merit, generally the top half of applications under
review, will be discussed and assigned a priority score
o Receive a written critique
o Receive a second level review by the appropriate advisory committee or
board.
REVIEW CRITERIA
The NIOSH R21 grant is a mechanism for supporting novel scientific ideas or
new model systems, tools or technologies that have the potential to
significantly advance our knowledge or the status of health-related research.
Because the research plan is limited to 15 pages, an R21 application need not
have extensive background material or preliminary information as one might
normally expect in an R01 application. Accordingly, reviewers will focus
their evaluation on the conceptual framework, the level of innovation, and the
potential to significantly advance our knowledge or understanding. Reviewers
will place less emphasis on methodological details and certain indicators
traditionally used in evaluating the scientific merit of R01 applications
including supportive preliminary data. Appropriate justification for the
proposed work can be provided through literature citations, data from other
sources, or, when available, from investigator-generated data. Preliminary
data are not required for R21 applications.
The goals of NIOSH-supported research are to deliver on the nation=s promise:
Safety and health at work for all people through research and prevention.
Specific goals toward that end are enumerated by priority area listed in the
Institute=s NORA. In the written comments, reviewers will be asked to discuss
the following aspects of the application in order to judge the likelihood that
the proposed research will have a substantial impact on the pursuit of these
goals:
o Significance
o Approach
o Innovation
o Investigator
o Environment
The scientific review group will address and consider each of these criteria
in assigning your application=s overall score, weighting them as appropriate
for each application. Your application does not need to be strong in all
categories to be judged likely to have major scientific impact and thus
deserve a high priority score. For example, you may propose to carry out
important work that by its nature is not innovative but is essential to move a
field forward.
SIGNIFICANCE: Does this study address an important problem? If the aims of the
application are achieved, how will scientific knowledge be advanced? What will
be the effect of these studies on the concepts or methods that drive this
field?
APPROACH: Are the conceptual framework, design, methods, and analyses
adequately developed, well-integrated, and appropriate to the aims of the
project? Does the applicant acknowledge potential problem areas and consider
alternative tactics?
INNOVATION: Does the project employ novel concepts, approaches or methods? Are
the aims original and innovative? Does the project challenge existing
paradigms or develop new methodologies or technologies?
INVESTIGATOR: Is the investigator appropriately trained and well suited to
carry out this work? Is the work proposed appropriate to the experience level
of the principal investigator and other researchers (if any)?
ENVIRONMENT: Does the scientific environment in which the work will be done
contribute to the probability of success? Do the proposed experiments take
advantage of unique features of the scientific environment or employ useful
collaborative arrangements? Is there evidence of institutional support?
ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, the following
items will be considered in the determination of scientific merit and the
priority score:
PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of human
subjects and protections from research risk relating to their participation in
the proposed research will be assessed. (See criteria included in the section
on Federal Citations, below).
INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy of plans
to include subjects from both genders, all racial and ethnic groups (and
subgroups), and children as appropriate for the scientific goals of the
research will be assessed. Plans for the recruitment and retention of
subjects will also be evaluated. (See Inclusion Criteria in the sections on
Federal Citations, below).
CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals are to
be used in the project, the five items described under Section f of the PHS
398 research grant application instructions (rev. 5/2001) will be assessed.
ADDITIONAL REVIEW CONSIDERATIONS
BUDGET: The reasonableness of the proposed budget and the requested period of
support in relation to the proposed research.
AWARD CRITERIA
Applications submitted in response to a PA will compete for available funds
with all other recommended applications. The following will be considered in
making funding decisions:
o Scientific merit of the proposed project as determined by peer review
o Availability of funds
o Relevance to program priorities
REQUIRED FEDERAL CITATIONS
HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that
applications and proposals involving human subjects must be evaluated with
reference to the risks to the subjects, the adequacy of protection against
these risks, the potential benefits of the research to the subjects and
others, and the importance of the knowledge gained or to be gained.
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of
the NIH that women and members of minority groups and their sub-populations
must be included in all NIH-supported clinical research projects unless a
clear and compelling justification is provided indicating that inclusion is
inappropriate with respect to the health of the subjects or the purpose of the
research. This policy results from the NIH Revitalization Act of 1993 (Section
492B of Public Law 103-43). NIOSH has adopted this policy for this
announcement.
All investigators proposing clinical research should read the "NIH Guidelines
for Inclusion of Women and Minorities as Subjects in Clinical Research -
Amended, October, 2001," published in the NIH Guide for Grants and Contracts
on October 9, 2001
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html);
a complete copy of the updated Guidelines are available at
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.
The amended policy incorporates: the use of an NIH definition of clinical
research; updated racial and ethnic categories in compliance with the new
Office of Management and Budget (OMB) standards; clarification of language
governing NIH-defined Phase III clinical trials consistent with the new PHS
Form 398; and updated roles and responsibilities of NIH staff and the
extramural community. The policy continues to require for all NIH-defined
Phase III clinical trials that: a) all applications or proposals and/or
protocols must provide a description of plans to conduct analyses, as
appropriate, to address differences by sex/gender and/or racial/ethnic groups,
including subgroups if applicable; and b) investigators must report annual
accrual and progress in conducting analyses, as appropriate, by sex/gender
and/or racial/ethnic group differences. NIOSH has adopted this policy for this
announcement.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS:
The NIH maintains a policy that children (i.e., individuals under the age of
21) must be included in all human subjects research, conducted or supported
by the NIH, unless there are scientific and ethical reasons not to include
them. This policy applies to all initial (Type 1) applications submitted for
receipt dates after October 1, 1998. NIOSH has adopted this policy for this
announcement.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the inclusion of children as participants in
research involving human subjects that is available at
http://grants.nih.gov/grants/funding/children/children.htm.
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH
policy requires education on the protection of human subject participants for
all investigators submitting NIH proposals for research involving human
subjects. You will find this policy announcement in the NIH Guide for Grants
and Contracts Announcement, dated June 5, 2000, at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html. NIOSH
has adopted this policy for this announcement.
HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of research on
hESCs can be found at http://stemcells.nih.gov/index.asp and at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only
research using hESC lines that are registered in the NIH Human Embryonic Stem
Cell Registry will be eligible for Federal funding (see http://escr.nih.gov).
It is the responsibility of the applicant to provide, in the project
description and elsewhere in the application as appropriate, the official NIH
identifier(s)for the hESC line(s)to be used in the proposed research.
Applications that do not provide this information will be returned without
review.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT (FOIA):
The OMB Circular A-110 has been revised to provide public access to research
data through the FOIA under some circumstances. Data that are (1) first
produced in a project that is supported in whole or in part with Federal
funds and (2) cited publicly and officially by a Federal agency in support of
an action that has the force and effect of law (i.e., a regulation) may be
accessed through FOIA. It is important for applicants to understand the
basic scope of this amendment. NIH has provided guidance at
http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this PA in a public
archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should
include a description of the archiving plan in the study design and include
information about this in the budget justification section of the
application. In addition, applicants should think about how to structure
informed consent statements and other human subjects procedures given the
potential for wider use of data collected under this award.
STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION: The
DHHS issued final modification to the Standards for Privacy of Individually
Identifiable Health Information , the Privacy Rule, on August 14, 2002. The
Privacy Rule is a federal regulation under Health Insurance Portability and
Accountability Act (HIPPA) of 1996 that governs the protection of
individually identifiable health information, and is administered and
enforced by the DHHS Office for Civil Rights (OCR). Those who must comply
with the Privacy Rule (classified under the Rule as covered entities ) must
do so by April 14, 2003 (with the exception of small health plans which have
an extra year to comply).
Decisions about applicability and implementation of the Privacy Rule reside
with the researcher and his/her institution. The OCR website
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including
a complete Regulation Text and a set of decision tools on Am I a covered
entity? Information on the impact of the HIPPA Privacy Rule on NIH processes
involving the review, funding, and progress monitoring of grants, cooperative
agreements, and research contracts can be found at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
INTERNET ADDRESS (URLs)IN NIH GRANT APPLICATIONS OR APPENDICES: All
applications and proposals for NIH funding must be self-contained within
specified page limitations. Unless otherwise specified in an NIH
solicitation, URLs should not be used to provide information necessary to the
review because reviewers are under no obligation to view the Internet sites.
Furthermore, we caution reviewers that their anonymity may be compromised
when they directly access an Internet site.
HEALTHY PEOPLE 2010: CDC is committed to achieving the health promotion and
disease prevention objectives of "Healthy People 2010," a national activity
for reducing morbidity and mortality and improve the quality of life. This
PA is related to one or more focus areas. Potential applicants may obtain a
copy of "Healthy People 2010" at http://www.healthypeople.gov/.
AUTHORITY AND REGULATIONS: This program is described in the CFDA at
http://www.cfda.gov/ and is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency review. Awards
are made under the authorization of Sections
301(a) [42 U.S.C. 241(a)], the Occupational Safety and Health Act of 1970,
Section 20(a) [29 U.S.C. 669(a)] [number: 93.262, Occupational Safety and
Health Research Grants of the National Institute for Occupational Safety and
Health (NIOSH)], and under Federal Regulations 42 CFR 52 and 45 CFR Parts
74 and 92.
LOBBYING RESTRICTIONS: Applicants should be aware of restrictions on the use
of HHS funds for lobbying of Federal or State legislative bodies. Under the
provisions of 31 U.S.C. Section 1352, recipients (and their subtier
contractors) are prohibited from using appropriated Federal funds (other than
profits from a Federal contract) for lobbying congress or any Federal agency
in connection with the award of a particular contract, grant, cooperative
agreement, or loan. This includes grants/cooperative agreements that, in whole
or in part, involve conferences for which Federal funds cannot be used
directly or indirectly to encourage participants to lobby or to instruct
participants on how to lobby.
In addition no part of PHS appropriated funds, shall be used, other than for
normal and recognized executive-legislative relationships, for publicity or
propaganda purposes, for the preparation, distribution, or use of any kit,
pamphlet, booklet, publication, radio, television, or video presentation
designed to support or defeat legislation pending before the Congress or any
State or local legislature, except in presentation to the Congress or any
State or local legislature itself. No part of the appropriated funds shall be
used to pay the salary or expenses of any grant or contract recipient, or
agent acting for such recipient, related to any activity designed to influence
legislation or appropriations pending before the Congress or any State or
local legislature.
Any activity designed to influence action in regard to a particular piece of
pending legislation would be considered lobbying. That is lobbying for or
against pending legislation, as well as indirect or grass roots: lobbying
efforts by award recipients that are directed at inducing members of the
public to contact their elected representatives at the Federal or State levels
to urge support of, or opposition to, pending legislative proposals is
prohibited. As a matter of policy, NIOSH/CDC extends the prohibitions to
lobbying with respect to local legislation and local legislative bodies.
The provisions are not intended to prohibit all interaction with the
legislative branch, or to prohibit educational efforts pertaining to public
health. Clearly there are circumstances when it is advisable and permissible
to provide information to the legislative branch in order to foster
implementation of prevention strategies to promote public health. However, it
would not be permissible to influence, directly or indirectly, a specific
piece of pending legislation.
It remains permissible to use NIOSH/CDC funds to engage in activity to enhance
prevention; collect and analyze data; publish and disseminate results of
research and surveillance data; implement prevention strategies; conduct
community outreach services; provide leadership and training; and foster safe
and healthful environments.
Recipients of NIOSH/CDC grants and cooperative agreements need to be careful
to prevent NIOSH/CDC funds from being used to influence or promote pending
legislation. With respect to conferences, public events, publication, and
grass roots activities that relate to specific legislation, recipients of
NIOSH/CDC funds should give attention to isolating and separating the
appropriate use of NIOSH/CDC funds from non-NIOSH/CDC funds. NIOSH/CDC also
cautions recipients of NIOSH/CDC funds to be careful not to give the
appearance that NIOSH/CDC funds are being used to carry out activities in a
manner that is prohibited under Federal law.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition, Public
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain
facilities (or in some cases, any portion of a facility) in which regular or
routine education, library, day care, health care, or early childhood
development services are provided to children. This is consistent with the
PHS mission to protect and advance the physical and mental health of the
American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
|
|
Department of Health and Human Services (HHS)
|
|
|
|
NIH... Turning Discovery Into Health®
|